EMEA-000980-PIP02-15

Key facts

Invented name
Adcetris
Active substance
Brentuximab vedotin
Therapeutic area
Oncology
Decision number
P/0168/2015
PIP number
EMEA-000980-PIP02-15
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of Cutaneous T-Cell Lymphoma
Route(s) of administration
Intravenous use
Contact for public enquiries
Takeda Pharma A/S
United Kingdom
Email: bharti.navsariwala@takeda.com
Tel.: +44 (0) 2031 168000
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating